Contribute Try STAT+ Today

Good morning, folks, and how are you today? We are doing just fine, thank you. A delicious cool breeze is wafting through the sunny Pharmalot campus, where the short person is busy hovering over a laptop and our official mascot is chasing wildlife — bunnies, chipmunks, squirrels, what have you. As for us, we are doing the usual — firing up the coffee kettle to make cups of stimulation, reviewing our to-do list. Perhaps you can relate. In any event, here are some tidbits for your consumption. Hope today goes well and you stay safe. …

The Trump administration chose five companies as the most likely candidates to produce a Covid-19 vaccine, a critical step in White House efforts to deliver on its promise of starting widespread inoculation of Americans by the end of the year, The New York Times tells us. The five companies are Moderna (MRNA); the combination of Oxford University and AstraZeneca (AZN), Johnson & Johnson (JNJ), Merck (MRK), and Pfizer (PFE). Among those left out were Sanofi (SNY), Inovio Pharmaceuticals (INO), and Novavax (NVAX).

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.